BIOIBÉRICA
9.3.2017 11:38:25 CET | Business Wire | Press release
“Everybody has heard of penicillin, but nobody knows what heparin is. And the fact is that heparin has saved as many lives as penicillin in the course of the 20 th century ”, explains Prof. Coen Hemker , a biochemist and Emeritus of the University of Maastricht, at the start of the documentary “Heparin: 100 years saving lives” . This 30-minute audiovisual recording has been directed by Carles Canet and produced by Broadcaster , with promotion from Bioibérica , to describe – on the basis of personal experiences – this anticoagulant drug which is so important in modern Medicine, having been declared a first-need drug by the World Health Organization.
In effect, this is the first documentary dedicated to this drug, and has been able to join the leading specialists and investigators in Hematology, Cardiology and Surgery, among other fields, as well as the drug industry, within one same audiovisual recording. Professionals from Spain (Hospital de la Santa Creu i Sant Pau , Hospital Universitari General de Catalunya , Hospital Germans Trias i Pujol , Banc de Sang i Teixits , Instituto Valenciano de Fertilidad , ISGlobal , IBEC ), the United States (Baylor University , Rensselaer Polytechnic Institute ), The Netherlands (Universidad de Maastricht , Synapse Research Institute ) and Italy (Instituto Ronzoni ), as well as international companies such as Sanofi , Laboratorios Rovi , BBraun or Bioibérica , have participated in the initiative
But the true central characters of this documentary are the patients who explain their own experiences: “I found it impossible to finish a training session and couldn’t believe that I would have to abandon water polo because of a clot in the subclavian vein at 17 years of age. Thanks to heparin, I was able to recover after six months, and everything that came afterwards was very much worthwhile”, explains Jennifer Pareja , a Spanish water polo player nominated the best player in the world in 2013.
The documentary can be seen online on Bioiberica website and is open to all those entities, educational institutions, organizations and people who wish to use and diffuse the recording. “Five out of every 10 people will need heparin at some point in life. Medicine wouldn’t be where it is today without it ”, explains Professor James Marcum , a historian at Baylor University in the United States.
Heparin , discovered in 1916, is a highly sulfated glycosaminoglycan – a natural substance composed of various molecules that inhibits blood clotting. Because of these properties, heparin is currently the most widely used drug for preventing and treating thrombosis. According to the International Society on Thrombosis and Hemostasis , one out of every four people in the world die of causes related to this disorder , which now produces more deaths each year than AIDS, breast cancer and traffic accidents combined.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170309005559/en/
Contact:
Bioibérica
Alba Soler i Conangla
+34 682 04 07
76 / +34 93 490 49 08
Communications Director
asoler@bioiberica.com
Visit
our press room
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting styrker sit cybersikkerhedstilbud gennem samarbejde med Trillium Information Security Systems21.3.2026 02:16:00 CET | Pressemeddelelse
Andersen Consulting udbygger sine kompetencer inden for teknologi og risikostyring gennem en samarbejdsaftale med Trillium Information Security Systems (TISS), et cybersikkerhedsfirma. Med en tilstedeværelse i Canada og Pakistan leverer TISS omfattende cybersikkerhedsløsninger til organisationer inden for finans, telekommunikation og den offentlige sektor. Virksomhedens team tilbyder et bredt udvalg af ydelser, herunder sikkerhedsvurderinger, managed security operations, red team-tjenester, digital efterforskning og hændelsesrespons samt GRC-rådgivning. Med næsten to årtiers erfaring leverer TISS adaptive, efterretningsdrevne forsvarsmekanismer, der hjælper kunder med at forudse og reagere på cybertrusler, der er i konstant udvikling. "Hos TISS arbejder vi på at skabe et mere sikkert digitalt miljø ved at give organisationer mulighed for at operere sikkert og med selvtillid," udtalte Mahir Mohsin Sheikh, administrerende direktør for TISS. "Vores samarbejde med Andersen Consulting giver
Andersen Consulting udvider sin teknologiplatform i Frankrig20.3.2026 17:28:00 CET | Pressemeddelelse
Andersen Consulting udvider sit udbud inden for digital transformation med en samarbejdsaftale med Teolia Consulting, et fransk firma, der specialiserer sig i projekt- og produktstyring, cloud-platformsudvikling, datatransformation samt implementering og brug af Atlassian-pakken. Teolia Consulting blev grundlagt i 2014 og hjælper organisationer med at opnå digital performance, fra agile metoder til løsninger, der reducerer lanceringstiden. Virksomhedens ekspertise består i at levere integrerede strategier, der bringer teknologi og organisatorisk forandring i overensstemmelse. Virksomheden arbejder på tværs af brancher, herunder inden for bank- og finanssektoren, forsikring, mode og detailhandel, og hjælper kunder med at få større robusthed og accelerere deres digitale modenhed. "Hos Teolia Consulting mener vi, at ægte transformation opstår, når teknologi og mennesker udvikler sig sammen," sagde Lucienne Jacquet, der er administrerende partner i Teolia. "Ved at samarbejde med Andersen C
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting20.3.2026 15:00:00 CET | Press release
- New, late-breaking 54-week data for povorcitinib in hidradenitis suppurativa (STOP-HS1 & STOP-HS2) to be highlighted - Featured abstracts for ruxolitinib cream (Opzelura®) and povorcitinib include multiple ePosters in atopic dermatitis, hidradenitis suppurativa and vitiligo Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver. “At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.” Details on key data presentation
MUSASHI JAPAN by TAIMATSU Launches “Road to Shogun” – A Journey Through Craftsmanship and Discovery20.3.2026 13:58:00 CET | Press release
Musashi Japan by TAIMATSU Co., Ltd., a contemporary Japanese knife brand rooted in the spirit of craftsmanship and cultural harmony, has announced its newest experiential campaign: “Road to Shogun.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320887471/en/ Designed as the brand’s most ambitious customer journey to date, the campaign invites visitors to explore participating Musashi Japan stores while discovering the traditions, culture and craftsmanship that inspire the brand. Inspired by the journey towards mastery, the experience encourages participants to progress through a series of ranks whilst visiting stores and unlocking rewards that celebrate elements of everyday Japanese culture. At Musashi Japan, craftsmanship is not only about the final product, but also about the path taken to achieve mastery. The Road to Shogun reflects this philosophy by guiding customers through a journey that mirrors the dedication, cu
Futur Delivers Strong Growth and Record Profit in 202520.3.2026 12:05:00 CET | Press release
In 2025, Futur added 21,000 new customers and the inflows amounted to 34 billion kronor. At the end of the year, the total savings capital was 252 billion kronor, an increase of 7% from the previous year and a new record level. "2025 was a record year for Futur. In a market characterized by sharp market fluctuations, Futur continued to invest, grow and deliver strong results. Behind this record performance is stable customer growth, strong inflows and cost discipline. Our close cooperation with over 60 partners gives customers the freedom to choose the asset management and advisory services that best suit them. The strategy of letting the customer choose is appreciated, which is reflected in us welcoming more than 21,000 new customers during the year", says Torgny Johansson, CEO of Futur. "We are optimistic about the future. Futur has great opportunities to continue growing in the coming years by developing innovative and efficient services for savings and pensions. I am proud of how a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
